Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.

World journal of gastroenterology - 28 Jan 2007

Witthoeft Th, Fuchs M, Ludwig D

Abstract excerpt

AIM: To investigate the use of high dose consensus-interferon in combination with ribavirin in former iv drug users infected with hepatitis C. METHODS: We started, before pegylated (PEG)-interferons were available, an open-label study to investigate the efficacy and tolerability of high dose induction therapy with consensus interferon (CIFN) and ribavirin in treatment of naiive patients with chronic hepatitis C....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon Type I

Share to Pilot Projects

Share to Quality of Life

Share to Ribavirin

Share to Substance Abuse, Intravenous

Source

Open in PubMed Open full text

Identifiers

PMID: 17278224
DOI: 10.3748/wjg.v13.i4.579
PMCID: PMC4065980

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.PMID 17278224Read ↗

Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.Semantic proximity Read ↗

A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.Semantic proximity Read ↗

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.Semantic proximity Read ↗

Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.Semantic proximity Read ↗

Daily interferon monotherapy for chronic hepatitis C in patients with normal or near-normal serum alanine transaminase levels: a comparison of two protocols.Semantic proximity Read ↗

Introduction: combination antiviral therapy in chronic hepatitis C.Semantic proximity Read ↗

Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.Semantic proximity Read ↗

Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2.Semantic proximity Read ↗

Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.Semantic proximity Read ↗

A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype.Semantic proximity Read ↗

High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.Semantic proximity Read ↗

Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.